This week, the Food and Drug Administration (FDA) approved two drugs that made the headlines because they were drugs that[…]
Read moreCategory: Payer Coverage
The U.S is Gearing up to Boost Drug Production – Five Key Considerations if You are Developing a New Drug.
To prevent the shortages that were a result of the COVID-19 pandemic, on February 24, 2021, President Biden signed Executive[…]
Read moreICD-10-PCS codes and guidelines for the 2022 fiscal year
The Centers for Medicare & Medicaid Services (CMS) published the final ICD-10-PCS codes and guidelines for the 2022 fiscal year[…]
Read moreWhat Does the Medicare Part D and its New Second Specialty Tier for High-Cost Drugs Mean for your Drug?
CMS has announced a final ruling that will revise regulations for the Medicare Advantage (MA or Part C) program and[…]
Read moreArkansas is Poised for Medicaid Managed Care Expansion in 2022? How will this Impact Market Access for your Product?
For over 19 years, GIRS has tracked payer trends to develop and implement market access strategies for our clients’ Products. […]
Read moreCheck out our FREE eBook!
We have created a free eBook just for you! Look at our short video for more details. You can also[…]
Read moreIs #Medtech prepared for 2021 Regulatory Changes?
Watch our short video to see some of the regulatory changes happening this year to create a healthcare system that[…]
Read more#Medtech Reimbursement Changes 2021: Medicare Advantage (MA) Changes for Beneficiaries with End-Stage Renal Disease (ESRD)
What does the future hold for #Medtech? Take a look at our short video with details regarding Medicare Advantage changes[…]
Read moreHow does the 2021 Physician Fee Schedule Impact #Medtech?
For more information, email us at info@girsinc.com or call us at 901-834-9119. On December 1, 2020, the Centers for Medicare[…]
Read moreIs #Medtech prepared for Payer Market Consolidation?
For more information, email us at info@girsinc.com or call us at 901-834-9119. GIRS tracks payer market mergers and other trends[…]
Read more